Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, Rahmy A, Masih KE, Kim YY, Belyea B, Linardic CM, Dropulic B, Sullivan PM, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL, Orentas RJ, Cheuk AT, Khan J.
Tian M, et al. Among authors: wu jt.
Cell Rep Med. 2024 May 21;5(5):101586. doi: 10.1016/j.xcrm.2024.101586. Epub 2024 May 9.
Cell Rep Med. 2024.
PMID: 38723625
Free PMC article.
No abstract available.